News

The Pharma Letter7h
Yeztugo holds potential to address key unmet needs for PrEP usage
Last week the US Food and Drug Administration approved Gilead Sciences Yeztugo (lenacapavir) for the prevention of HIV ...
Pharmaceutical Technology37m
Gilead eyes Kymera’s ‘adhesive’ cancer drug in $750m deal
Kymera’s programme focuses on removing CDK2 from cells compared to other therapies that target the protein’s inhibition.
A University of Utah doctor’s research led to a major HIV drug. He worries federal cuts will stop people from getting it.
The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...
The Observer10h
Ugandan firm to manufacture $28,000 HIV drug for just $50
In a bold step toward global health justice, Ugandan biotech company DEI BioPharma has announced it will begin manufacturing ...
Safeguarding the windows to the soul
Stay informed on health matters with Zubeda Hamid's newsletter covering cataract surgeries, maternal health, and medical ...
San Francisco Examiner5h
Coverage questions mute enthusiasm for HIV drug approval
Lenacapavir, created by Foster City-based Gilead Sciences, has been in use for several years as a treatment for HIV/AIDS ...